Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis

An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease

Open-Label Extension of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis

Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

Vedolizumab Subcutaneous Long-Term Open-Label Extension Study

A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease

A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis